India Closes In With US Companies For Investment In Pharmaceutical And Medical Device Sector | India News
WASHINGTON: India has reached out to major US pharmaceutical companies seeking investment in the country’s pharmaceutical and medical device sector, gaining in urgency in the face of a devastating second wave of the coronavirus pandemic.
Ambassador of India to the United States Taranjit Singh Sandhu has held virtual meetings with Alberta Bourla, CEO of Pfizer, Thermo Fisher CEO Marc Casper, Bernd Brust, Antylia Scientific President and CEO, and Joseph Repp, Pall CEO life sciences.
He also had a call with Emmanuel Ligner, CEO and President of Cytiva.
During his interactions with pharmaceutical companies, Sandhu mentioned that India seeks to encourage investments in the pharmaceutical and medical device sector.
India, he said, has recently launched a production-linked incentive scheme that will provide US companies with new investment opportunities.
“We discussed ways that Pfizer could support healthcare efforts, including vaccines in India, and strengthen our response to the pandemic,” Sandhu said after meeting with Bourla last week.
On Monday, Bourla had said that Pfizer was following the critical COVID-19 situation in India with deep concern and that his company was doing everything possible to provide support.
“Today we announce that we are mobilizing the largest humanitarian aid effort in our company’s history to help the people of India combat the vicious second wave of coronavirus that is currently ravaging the nation,” he said.
Among other things, it announced that it will donate a sufficient amount of its medicines worth $ 70 million to ensure that all COVID-19 patients in all public hospitals in India can access them within the next 90 days for free. .
“This effort has the potential to impact the lives of hundreds of thousands of patients,” Bourla said.
In his meeting with Thermo Fisher CEO Marc Casper, Sandhu underscored his important role in fighting the pandemic, including shipping supplies to India of raw materials for Covishield vaccine, as well as essential drugs such as remdesivir.
Thermo Fisher, based in Massachusetts, is a key player in the biopharmaceutical supply chain. It offers analytical instruments, laboratory equipment, chemicals and supplies to pharmaceutical and biotechnology companies, hospitals and clinical diagnostic laboratories, universities, research institutions and government agencies.
During his meeting with Repp, CEO of Pall Life Sciences, the Indian Ambassador spoke about strengthening supply chains and streamlining supplies for critical medicines such as remdesivir and Novavax vaccine.
Pall’s biotech products have played a key role in life-saving drugs ranging from Ebola vaccines to monoclonal antibodies that cure cancer. Its products are highly relevant given the current pandemic situation and are part of critical supply chains in the industry.
The company has an extensive network in India, including offices in Mumbai, Ahmedabad, Hyderabad, Chandigarh, Delhi and Bangalore.
Sandhu, in his call with Bernd Brust, President and CEO of Antylia Scientific, thanked his company’s efforts to ensure timely supplies for the Covishield and Novavax vaccines.
Antylia Scientific is a global expert in single-use and peristaltic bioprocessing solutions, with a diverse portfolio of diagnostic and life science products for the pharmaceutical, biopharmaceutical, healthcare and environmental markets.
The ambassador also had a call with Emmanuel Ligner, the CEO and president of Cytiva, which is a global provider of technologies and services that advance and accelerate the development and manufacturing of therapies.